Selenase Effect on patients with septic shock

Evaluation of selenase on improving process of septic shock patients in ImamReza hospital of AJA

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014030916906N1

Enrollment

Registered

2014-06-26

Start date

2013-10-11

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with septic shock. Septic shock

Interventions

Intervention 1: Each of the subjects in the treatment group will be treated with the selenae drug for 10 days 500µg rate twice daily . Intervention 2: Each of the control group were treated twice dai

Treatment - Drugs

Placebo

Each of the subjects in the treatment group will be treated with the selenae drug for 10 days 500µg rate twice daily .

Each of the control group were treated twice daily for 10 days with placebo(salin normal0/9%) .

Eligibility

Sex/Gender

All

Age

20 Years to 90 Years

Inclusion criteria

Inclusion criteria: Conditions of entering the study: all male and female patients with septic shock Aged 20 -90 years old admitted in the Army 501 Hospital in Tehran, Iran; signing informed consent form to participate in the research project by the patient or in case of absence or inability of the patient's conscious decision to treat has been signed first-degree relatives. And there is one case: a positive bacterial culture, pyuria, positive scintigraphy, abscesses, pneumonia, cellulitis, gangrene, wound infection, urinary catheters Exclusion criteria: patients with chronic end stage, dialysis patients; pregnant women; active gastrointestinal bleeding and patients post- CPR.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Prolactin. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the laboratory test unit.;C reactive protein(CRP). Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the laboratory test unit.;Platelets. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Laboratory - platelet counts and peripheral blood smears in certain units.;Causing the infection. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the positive part of the culture.	—

Measure

Time frame

Prolactin. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the laboratory test unit.;C reactive protein(CRP). Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the laboratory test unit.;Platelets. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Laboratory - platelet counts and peripheral blood smears in certain units.;Causing the infection. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Based on the positive part of the culture.

—

Secondary

Measure	Time frame
Pao2 /Fio2. Timepoint: Before treatment (intervention) - After the end of treatment. Method of measurement: Evaluation based on ABG values.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBehzad Kazemi Haki

Tabriz University of Medical Sciences

behzad_emt@yahoo.com+98 914 938 0765

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026